US stock results analysis for Industry - Specialty Pharmaceuticals for the month ending Dec 31, 2025
Analysis of which US stocks have performed the best and worst in Industry - Specialty Pharmaceuticals for the month ending Dec 31, 2025 on the basis of sales/revenues, profits and profit margins. Only companies which have declared results in the current month are considered.
0
POSITIVE PROFIT GROWTH
1
NEGATIVE PROFIT GROWTH
0
NEUTRAL PROFIT GROWTH
0
%
TOTAL REVENUE GROWTH
0
%
TOTAL EBIDT GROWTH
-24.4
%
TOTAL OPER. PROFIT GROWTH
Positive
Negative
Pending
| Stock | Last Result Updated | Market Capitalization | Current Price | Operating Revenue Qtr | Revenue Growth Qtr YoY % | Revenue Surprise Qtr % | Net Profit Qtr | Net Profit Qtr Growth YoY % | Net Profit Surprise Qtr % | Operating Profit Qtr | Operating Profit Growth Qtr YoY % | EBITDA Qtr | EBITDA Qtr growth YoY % | Operating Profit Margin Qtr % | Operating Profit Qtr Margin% YoY Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PharmaCyte Biotech Inc | 18-Dec-2025 |
8.61
|
0.85
|
0.00
|
-
|
-
|
-7.42
|
-404.78
|
-
|
-1.38
|
-24.41
|
0.00
|
-
|
-
|
-
|
